Skip to content
  • Tuesday, 30 June 2026
  • 10:31 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Eli Lilly and Profluent Partner to Harness AI for Advanced Recombinase-Based Gene Editing
Pharmaceutical R&D

Eli Lilly and Profluent Partner to Harness AI for Advanced Recombinase-Based Gene Editing

Teuku Ryan Apr 29, 2026 0

Eli Lilly and Company, a global leader in pharmaceutical innovation, has announced a significant strategic alliance with Profluent, an artificial…

Read More
Kyowa Kirin Secures FDA Approval for Enhanced Crysvita Dosing Regimen for Adults with X-Linked HypophosphatemiaThe Hidden Skill Gap: Why SQL and Python Are No Longer Enough for Data ProfessionalsGlucose Revealed as a Master Regulator of Tissue Differentiation in Landmark Stanford Medicine StudySalesforce lands 140 life sciences clients, pitches ‘headless’ AI to pharma
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveHigh-Dimensional Topological Structures Discovered in Entangled Photons Offer New Framework for Quantum Information StabilityWater-in-Diesel Emulsion Technology Offers Significant Emissions Reduction Potential Without Engine Modification
Glioblastoma Research Reveals Skull Erosion and Immune System Reprogramming Reshaping Treatment StrategiesPioneering Sequencing by Synthesis: David Klenerman Reflects on a Decade of Innovation and the Future of BiotechDiabetes to MASH: the specimens behind GLP-1’s widening rosterSeven Pharma Companies Selected for FDA PreCheck Pilot Program to Bolster U.S. Drug Supply Chain
YOU MAY HAVE MISSED
Stem Cell & Regenerative Medicine
Glioblastoma Research Reveals Skull Erosion and Immune System Reprogramming Reshaping Treatment Strategies
Dwi Wanna Jun 30, 2026
Biotech & Genetic Research
Pioneering Sequencing by Synthesis: David Klenerman Reflects on a Decade of Innovation and the Future of Biotech
Jia Lissa Jun 30, 2026
Laboratory Automation & Robotics
Diabetes to MASH: the specimens behind GLP-1’s widening roster
Lana Keisha Jun 30, 2026
Pharmaceutical R&D
Seven Pharma Companies Selected for FDA PreCheck Pilot Program to Bolster U.S. Drug Supply Chain
Teuku Ryan Jun 30, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ